Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy

11 Jan 2023

Abstract excerpt

Assessment of anti-adeno-associated virus (AAV) antibodies in patients prior to systemic gene therapy administration is an important consideration regarding efficacy and safety of the therapy. Approximately 30%–60% of individuals have pre-existing anti-AAV antibodies. Seroprevalence is impacted by multiple factors, including geography, age, capsid serotype, and assay type. Anti-AAV antibody assays typically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36635967
DOI: 10.1016/j.ymthe.2023.01.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapyPMID 36635967Read ↗

Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirementsSemantic proximity Read ↗

Rapid Detection of AAV8 Binding Antibodies in Gene Therapy Candidates: Development of a Point-of-Care ApproachSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypesSemantic proximity Read ↗

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsSemantic proximity Read ↗

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Semantic proximity Read ↗

Strategy to detect pre-existing immunity to AAV gene therapySemantic proximity Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding AssaySemantic proximity Read ↗

Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trialsSemantic proximity Read ↗

Humoral immune responses to AAV gene therapy in the ocular compartmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.